UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial

European radiology, 2021-04, Vol.31 (4), p.1853-1862

2021

Volltextzugriff (PDF)

Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration

CPT: pharmacometrics and systems pharmacology, 2023-07, Vol.12 (7), p.929-940

2023

Volltextzugriff (PDF)

Disparities in molecular tumor board recommendations and treatment implementation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18582-e18582

2023

Volltextzugriff (PDF)

Get Real: Integration of Real‐World Data to Improve Patient Care

Clinical pharmacology and therapeutics, 2020-04, Vol.107 (4), p.722-725

2020

Volltextzugriff (PDF)

Abstract PO022: Multidimensional longitudinal assessment of patients under treatment for advanced endometrial cancer: a new tool to advance research on human disease

Clinical cancer research, 2021-02, Vol.27 (3_Supplement), p.PO022-PO022

2021

Volltextzugriff (PDF)

Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis

JAMA oncology, 2022-03, Vol.8 (3), p.385

2022

Volltextzugriff (PDF)

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation

Clinical cancer research, 2020-12, Vol.26 (24), p.6464-6474

2020

Volltextzugriff (PDF)

Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer

Gynecologic oncology, 2021-01, Vol.160 (1), p.295-301

2021

Volltextzugriff (PDF)

An imaging signature to predict outcome in metastatic colorectal cancer using routine CT scans

European journal of cancer (1990), 2021-12, Vol.161, p.138-147

2021

Volltextzugriff (PDF)

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.361-361

2021

Volltextzugriff (PDF)

Abstract 5451: Longitudinal proteomic assessment of patient with metastatic apocrine adenocarcinoma reveals evolutionary selection for androgen-receptor-dependence and therapeutic response

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5451-5451

2020

Volltextzugriff (PDF)

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

British journal of cancer, 2018-04, Vol.118 (8), p.1042-1050

2018

Volltextzugriff (PDF)

Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics

JNCI : Journal of the National Cancer Institute, 2015-11, Vol.107 (11), p.djv247

2015

Volltextzugriff (PDF)

Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3581-3581

2018

Volltextzugriff (PDF)

Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2563-2563

2017

Volltextzugriff (PDF)

Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies

Clinical pharmacology and therapeutics, 2014-07, Vol.96 (1), p.27-35

2014

Volltextzugriff (PDF)

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Clinical cancer research, 2015-11, Vol.21 (22), p.5092-5099

2015

Volltextzugriff (PDF)

Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors

Journal of clinical pharmacology, 2014-06, Vol.54 (6), p.682-687

2014

Volltextzugriff (PDF)

Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2571-2571

2013

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Aktive Filter

ThemaCancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(19)

Sprache

Englisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial

Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration

Disparities in molecular tumor board recommendations and treatment implementation

Get Real: Integration of Real‐World Data to Improve Patient Care

Abstract PO022: Multidimensional longitudinal assessment of patients under treatment for advanced endometrial cancer: a new tool to advance research on human disease

Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation

Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer

An imaging signature to predict outcome in metastatic colorectal cancer using routine CT scans

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202

Abstract 5451: Longitudinal proteomic assessment of patient with metastatic apocrine adenocarcinoma reveals evolutionary selection for androgen-receptor-dependence and therapeutic response

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics

Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT)

Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib

Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors

Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors

Aktive Filter

Suchergebnisse filtern